Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy

NCT03234465 is registered in ClinicalTrials.gov with Oragenics, Inc. as lead sponsor.

NCT NCT03234465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03234465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy
Lead sponsor
Oragenics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 18, 2017
Completion date
July 13, 2020
Enrollment
200 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

oral mucositis